Reference health
Osteosarcoma, Chondrosarcoma, and Chordoma
56/56 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
2 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 56 checked references that resolve
resolves10.1002/ijc.24320
International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons
resolves10.1056/NEJM198606193142502
The Effect of Adjuvant Chemotherapy on Relapse-Free Survival in Patients with Osteosarcoma of the Extremity
resolves10.1200/JCO.2008.14.0095
Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival—A Report From the Children's Oncology Group
resolves10.1200/JCO.2014.60.0734
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial
resolves10.1002/1097-0142(197601)37:1<1::AID-CNCR2820370102>3.0.CO;2-3
Chemotherapy,en bloc resection, and prosthetic bone replacement in the treatment of osteogenic sarcoma
resolves10.1016/j.ijrobp.2015.10.025
Proton Therapy in Children: A Systematic Review of Clinical Effectiveness in 15 Pediatric Cancers
resolves10.1016/S1470-2045(16)30214-5
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial
resolves10.1093/annonc/mdu526
EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment
resolves10.1200/JCO.2012.43.8598
Benefits and Adverse Events in Younger Versus Older Patients Receiving Neoadjuvant Chemotherapy for Osteosarcoma: Findings From a Meta-Analysis
resolves10.1002/pbc.20032
High‐dose methotrexate therapy of childhood acute lymphoblastic leukemia: Lack of relation between serum methotrexate concentration and creatinine clearance
resolves10.1245/s10434-013-3210-4
Prognostic Factors in Elderly Osteosarcoma Patients: A Multi-institutional Retrospective Study of 86 Cases
resolves10.1200/JCO.2003.08.132
Primary Metastatic Osteosarcoma: Presentation and Outcome of Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols
resolves10.1200/JCO.2002.20.3.776
Prognostic Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1,702 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols
resolves10.1200/JCO.1998.16.11.3641
Treatment of metastatic osteosarcoma at diagnosis: a Pediatric Oncology Group Study.
resolves10.1016/j.ejca.2010.11.036
Survival after recurrent osteosarcoma: Data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials
resolves10.1200/JCO.2005.04.063
Osteosarcoma Relapse After Combined Modality Therapy: An Analysis of Unselected Patients in the Cooperative Osteosarcoma Study Group (COSS)
resolves10.1200/JCO.2015.65.5381
Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward
resolves10.1200/JCO.2003.03.141
Postrelapse Survival in Osteosarcoma of the Extremities: Prognostic Factors for Long-Term Survival
resolves10.1186/s12885-016-2312-3
Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone
resolves10.1200/JCO.2002.20.2.521
Extraosseous Osteosarcoma: Response to Treatment and Long-Term Outcome
resolves10.1007/s11999-015-4463-y
Should High-grade Extraosseous Osteosarcoma Be Treated With Multimodality Therapy Like Other Soft Tissue Sarcomas?
resolves10.1007/s00432-005-0687-7
Extraskeletal osteosarcoma has a favourable prognosis when treated like conventional osteosarcoma
resolves10.1016/j.ejca.2016.12.016
Extraskeletal osteosarcoma: A European Musculoskeletal Oncology Society study on 266 patients
resolves10.1200/JCO.1997.15.1.363
Effect of chemotherapy on survival of craniofacial osteosarcoma: a systematic review of 201 patients.
resolves10.1186/1471-2407-14-23
Is [F-18]-fluorodeoxy-D-glucose positron emission tomography of value in the management of patients with craniofacial bone sarcomas undergoing neo-adjuvant treatment?
resolves10.1200/JCO.1999.17.10.3260
Neoadjuvant Chemotherapy With Doxorubicin and Cisplatin in Malignant Fibrous Histiocytoma of Bone: A European Osteosarcoma Intergroup Study
resolves10.1016/j.ejca.2004.08.026
Doxorubicin and cisplatin chemotherapy in high-grade spindle cell sarcomas of the bone, other than osteosarcoma or malignant fibrous histiocytoma: a European Osteosarcoma Intergroup Study
resolves10.1007/s00262-016-1925-3
Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy
resolves10.1158/1078-0432.CCR-10-2047
Tumor-Infiltrating Macrophages Are Associated with Metastasis Suppression in High-Grade Osteosarcoma: A Rationale for Treatment with Macrophage Activating Agents
resolves10.1158/1078-0432.CCR-10-0662
Inhaled Granulocyte-Macrophage Colony Stimulating Factor for First Pulmonary Recurrence of Osteosarcoma: Effects on Disease-Free Survival and Immunomodulation. A Report From the Children's Oncology Group
resolves10.1002/pbc.24438
Inhaled lipid cisplatin (ILC) in the treatment of patients with relapsed/progressive osteosarcoma metastatic to the lung
resolves10.1158/1078-0432.CCR-13-2574
Toward a Drug Development Path That Targets Metastatic Progression in Osteosarcoma
resolves10.1038/ncomms15936
Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma
resolves10.1038/srep30093
Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma
resolves10.1016/S1470-2045(14)71136-2
Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial
resolves10.1002/path.2913
<i>IDH1</i> and <i>IDH2</i> mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours
resolves10.1016/j.ejca.2014.11.007
Mesenchymal chondrosarcoma: Prognostic factors and outcome in 113 patients. A European Musculoskeletal Oncology Society study
resolves10.1016/j.ejca.2017.03.037
Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF)
resolves10.1158/2326-6066.CIR-15-0119
Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury
resolves10.1093/annonc/mdx054
Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group
resolves10.1016/S1470-2045(14)71190-8
Building a global consensus approach to chordoma: a position paper from the medical and patient community
The 2 references without a DOI — listed, not checked
no DOI — not checkedFletcher CDM, Bridge JA, Hogendoorn P, et al (eds): WHO classification of tumours of soft tissue and bone, 4th ed. Lyon, France, IARC Press, 2013.
no DOI — not checkedB16a
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1200/jco.2017.75.1743"><img src="https://citestamp.com/citestamped/10.1200/jco.2017.75.1743/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1200/jco.2017.75.1743)